TAMURA HIDETO

Profiles

Profiles

• 氏名

  TAMURA HIDETO

Affiliation

• Department of Diabetes, Endocrinology and Hematology, Professor

Research achievements

Published Papers

Original paper
• SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma, Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H., Mol Cancer Res., 18(4), 632-643, Apr. 2020

  DOI
• A Combination of Check-Point Blockade and α-Galactosylceramide Elicits Long-Lasting Suppressive Effects on Murine Hepatoma Cell Growth in Vivo, Ishii K, Shimizu M, Kogo H, Negishi Y, Tamura H, Morita R, Takahashi H., Immunobiology., 225(1), 151860, Jan. 2020

  DOI
• Notch1–JAG1 signaling induces aggressive myeloma cell behaviors. Notch1–JAG1 signaling induces aggressive myeloma cell behaviors., Ishibashi M, Ueda K, Imai Y, Inokuchi K, Morita R, Tamura H, Int J Myeloma, 10(1), 1-7, 01 Oct. 2020
• Clinicopathologic characteristics and A20 mutation in primary thyroid lymphoma., Kuribayashi-Hamada Y，Ishibashi M，Tatsuguchi A，Asayama T，Takada- Okuyama N，Onodera-Kondo A，Moriya K，Igarashi T，Onose H，Tanosaki S， Yokose N，Yamaguchi H，Tamura H, J Nippon Med Sch．, 89(3), 301-308, Jun. 2022
• CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia., Kaito Y, Hirano M, Futami M, Nojima M, Tamura H, Tojo A, Imai Y, Oncol Lett., 23(2), 51, Feb. 2022

  DOI
• A case of persistent SARS-CoV-2 PCR positive after chemotherapy for B-cell lymphoma．, Hirokawa H，Hirata H，Kitajima R，Irokawa M，Ishiguro T，Hasegawa T，Sato J， Ozaki A，Arima M，Teramoto S，Haruki K，Okamura T，Tamura H，Hashimoto K， Fukushima Y., Dokkyo Med J., 1, Jun. 2022
• Serum soluble CD86 levels correlate with CD86 variant 3 gene expression and are prognostic indicators in myeloma. Exp Hematol, Kinoshita R, Ishibashi M, Handa H, Sasaki M, Imai Y, Tanaka N, Ito S, Sunakawa-Kii M, Kaito Y, Asayama T, Komatsu N, Tanaka J, Odajima T, Sugimori H, Yamaguchi H，Inokuchi K, Tamura H, Exp Hematol., Feb. 2023

  DOI
• Serum soluble CD86 levels correlate with CD86 variant 3 gene expression and are prognostic indicators in myeloma., Kinoshita R, Ishibashi M, Handa H, Sasaki M, Imai Y, Tanaka N, Ito S, Sunakawa-Kii M, Kaito Y, Asayama T, Komatsu N, Tanaka J, Odajima T, Sugimori H, Yamaguchi H，Inokuchi K, Tamura H, Exp Hematol., (121), 38-47, 2023
• Immune checkpoint molecule DNAM-1/CD112 axis is a novel target of NK-cell therapy in acute myeloid leukemia., Kaito Y, Sugimoto E, Nakamura F, Tsukune Y, Sasaki M, Yui S, Yamaguchi H, Goyama S, Nannya Y, Mitani K, Tamura H, Imai Y., Haematologica., 7(s3), e2665764, 2023

Review paper
• What can be done to improve cancer immunotherapies?, Tamura H., Int J Hematol., 117(5), 631-633, 2023

Other
• PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma, Tamura H, Ishibashi M, Sunakawa-Kii M, Inokuchi K., Cancers, 12(4), 924, Apr. 2020

  DOI
• 80(2), 226-233, Feb. 2020

Unclear
• Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma., Ishibashi Mariko;Morita Rimpei;Tamura Hideto, Cancers, 13(2), 13 Jan. 2021

  DOI
• The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma., Ishibashi Mariko;Sunakawa-Kii Mika;Kaito Yuta;Kinoshita Ryosuke;Asayama Toshio;Kuribayashi Yasuko;Inokuchi Koiti;Morita Rimpei;Tamura Hideto, Experimental hematology, 90, 72-79, 17 Aug. 2020

  DOI
• PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma., Tamura Hideto;Ishibashi Mariko;Sunakawa-Kii Mika;Inokuchi Koiti, Cancers, 12(4), 10 Apr. 2020

  DOI
• Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes., Kobayashi Sumiko;Ueda Yasunori;Nannya Yasuhito;Shibayama Hirohiko;Tamura Hideto;Ogata Kiyoyuki;Akatsuka Yoshiki;Usuki Kensuke;Ito Yoshikazu;Okada Masaya;Suzuki Takahiro;Hata Tomoko;Matsuda Akira;Tohyama Kaoru;Kakumoto Keiji;Koga Daisuke;Mitani Kinuko;Naoe Tomoki;Sugiyama Haruo;Takaku Fumimaro, Cancer biomarkers : section A of Disease markers, 17(1), 21-32, 31 Mar. 2016

  DOI

Books etc

• Contributor, 01 Sep. 2020, 146, 33-34, Scholarly book, 978-4-8306-2061-4
• Contributor, 01 Dec. 2020, 660, Scholarly book, 978-4-498-22524-4

Presentations

• Adenosine induces myeloma cell apoptosis due to decreased expression of PIM-2 and Myc, Sunakawa M，Ishibashi M，Kinoshita R，Kaito Y，Tanaka K，Akuzawa Y，Okura M， Okamura T，Kiguchi T，Hashimoto K，Tamura H, 14 Oct. 2022
• Primary survival analysis of Japanese patients with plasma cell neoplasms in novel drugs era, Shibayama H，Itagaki M，Handa H，Yokoyama A，Saito A，Kosugi S，Ota S， Yoshimitsu M，Tanaka Y，Kurahashi S，Fuchida S，Iino M，Shimizu T，Moriuchi Y， Toyama K，Mitani K，Tsukune Y，Kada A，Tamura H，Abe M，Iwasaki H，Kuroda J， Takamatsu H，Sunami K，Kizaki M，Ishida T，Saito T，Matsumura I，Akashi K， Iida S., 14 Oct. 2022, Oral presentation
• Extracellular low pH and adenosine in myeloma microenvironments induce tolerogenic dendritic cells, Ishibashi M，Morita R，Sunakawa M，Tamura H, 15 Oct. 2022
• Immune Checkpoint Molecule Signaling and Immunotherapy in Multiple Myeloma., Tamura H, Ishibashi M, Imai Y., The 13th JSH International Symposium, 21 Jul. 2023, 21 Jul. 2023, 22 Jul. 2023, JSH, Japan, True

Social contributions

Media Coverage

• Internet, Myself, 13 May 2021